The presence of the drug in Oz is sparking significant excitement within the healthcare community. This novel dual medication – targeting both GLP-1 and GIP receptors – presents a potentially powerful approach for https://fellowfavorite.com/story23460720/new-retatrutide-australia-a-fresh-solution-for-weight-management